The recombinant subunit vaccine RBD-Fc, consisting of SARS-CoV-2 RBD and human IgG Fc as an immunopotentiator, elicits robust neutralizing antibody responses against SARS-CoV-2 infection
Zezhong Liu(Ministry of Education), Shibo Jiang(Shanghai Medical College of Fudan University), Shuai Xia(Shanghai Medical College of Fudan University), Tianlei Ying(Shanghai Medical College of Fudan University), Di Qu(Harbin Medical University), Yan‐Ling Wu(Yanbian University), Zhenghong Yuan(Shanghai Medical College of Fudan University), Lu Lu(Shanghai Medical College of Fudan University), Qian Wang(Shanghai Medical College of Fudan University), Xinling Wang(Fudan University), Youhua Xie(Fudan University), Chenjian Gu(Washington University in St. Louis), Wei Xu(Beijing Geriatric Hospital), Xia Cai(Fudan University), Jie Zhou(Imperial College London)
Cited by 2
Related Papers
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
|New England Journal of Medicine|2013|2.4k
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
|Nature|2021|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647